Farideh Bischoff, PhD
Chief Medical Officer – Diagnostics
Farideh received her Ph.D. in Cancer Biology from University of Texas Graduate School for Biomedical Sciences (Houston, TX) followed by postdoctoral training at M.D. Anderson Cancer Center and Baylor College of Medicine.
She has over 25 years’ experience in the development and validation of noninvasive prenatal and oncology assays intended for clinical application/commercialization. She’s clinically trained in human molecular genetics and cytogenetic, and has served as full-time faculty in the Departments of Obstetrics and Gynecology, and Immunology at Baylor College of Medicine, where her work in fetal cells began as a key investigator on the NIH sponsored Fetal Cell (NIFTY) Study, paving the way for integration of non-invasive testing during pregnancy.
Farideh has managed many research projects, including studies to elucidate underlying genetic components of endometriosis, infertility/pre-implantation genetic diagnosis, and non-invasive prenatal genetic diagnostics. Farideh is a visionary and also known in the fields of circulating rare tumor (CTC) cells and DNA as a source for non-invasive molecular diagnostic testing to support therapy selection, prognosis and patient monitoring. She has over 300 peer reviewed publications, conference submissions and book chapters.
Over her career, she has provided mentorship to numerous students, residents, and fellows, as well as leadership to executive teams seeking and assessing technology alliances with appropriate academic and commercial partners. Farideh began her research career at MD Anderson Cancer Center (Houston, TX) with research and publications that led to the discovery of germline mutations in the p53 tumor suppressor gene giving rise to a now well-known cancer syndrome.
Farideh has received many awards and honors, including the Outstanding Merit Award in Basic Science Research (1993, M.D. Anderson Cancer Center, Houston, TX), the Charles A. Hunter Award (1998, The American Gynecological and Obstetrical Society), and The Women’s FUND for Health, Education and Research (HER) Award (1999, Genetics of Ovarian and Endometrial Cancer).
Most recently, as Chief Executive Officer and Chief Scientific Officer of FreMon Scientific, Inc., she led the successful regulatory and FDA 510K submission/ clearance process for the company’s first commercial product, ZipThaw202. In parallel, she successfully transitioned the company from R&D to commercial stage with US manufacturing and global sales all during the global COVID-19 pandemic.
She has over 25 years’ experience in the development and validation of noninvasive prenatal and oncology assays intended for clinical application/commercialization. She’s clinically trained in human molecular genetics and cytogenetic, and has served as full-time faculty in the Departments of Obstetrics and Gynecology, and Immunology at Baylor College of Medicine, where her work in fetal cells began as a key investigator on the NIH sponsored Fetal Cell (NIFTY) Study, paving the way for integration of non-invasive testing during pregnancy.
Farideh has managed many research projects, including studies to elucidate underlying genetic components of endometriosis, infertility/pre-implantation genetic diagnosis, and non-invasive prenatal genetic diagnostics. Farideh is a visionary and also known in the fields of circulating rare tumor (CTC) cells and DNA as a source for non-invasive molecular diagnostic testing to support therapy selection, prognosis and patient monitoring. She has over 300 peer reviewed publications, conference submissions and book chapters.
Over her career, she has provided mentorship to numerous students, residents, and fellows, as well as leadership to executive teams seeking and assessing technology alliances with appropriate academic and commercial partners. Farideh began her research career at MD Anderson Cancer Center (Houston, TX) with research and publications that led to the discovery of germline mutations in the p53 tumor suppressor gene giving rise to a now well-known cancer syndrome.
Farideh has received many awards and honors, including the Outstanding Merit Award in Basic Science Research (1993, M.D. Anderson Cancer Center, Houston, TX), the Charles A. Hunter Award (1998, The American Gynecological and Obstetrical Society), and The Women’s FUND for Health, Education and Research (HER) Award (1999, Genetics of Ovarian and Endometrial Cancer).
Most recently, as Chief Executive Officer and Chief Scientific Officer of FreMon Scientific, Inc., she led the successful regulatory and FDA 510K submission/ clearance process for the company’s first commercial product, ZipThaw202. In parallel, she successfully transitioned the company from R&D to commercial stage with US manufacturing and global sales all during the global COVID-19 pandemic.
